| Date | Quarter | Session | EPS (est → actual) | Revenue (est → actual) |
|---|---|---|---|---|
| Oct 27, 2026Next | Q3 2026 | After market close | 3.61 | 3.54 B |
Aug 31, 2026
Outpatient and home healthcare stocks gain from aging, digital care and AI, with LifeStance, Option Care, Aveanna and DaVita in focus.
Aug 28, 2026
An aging population and growing telehealth and AI adoption support the Zacks Medical - Outpatient and Home Healthcare industry. DVA, LFST, OPCH and AVAH stand to benefit.
Aug 26, 2026
DaVita expands its Humana partnership to earlier-stage kidney disease, bringing value-based care to over 10,000 Medicare Advantage members.
Aug 25, 2026
Humana stock has delivered a strong 46.2% return year to date, yet the valuation checks paint a mixed picture that leaves investors weighing how much of the story is already reflected in the price. Year to date, Humana is up 46.2%, which puts recent gains front and centre for anyone assessing what the current valuation implies. Recent moves such as the value based partnership with DaVita and the appointment of a new Chief Medical Officer may support confidence in Humana's care model and...
DaVita (NYSE:DVA) has expanded its partnership with Humana (NYSE:HUM) through a new value-based care agreement covering more than 10,000 Medicare Advantage members living with chronic kidney disease. The programme, which launched on July 1, targets patients with stages 3B through 5 chronic kidney disease (CKD).
DaVita today announced a new value-based care agreement to deliver comprehensive, coordinated care to Humana Medicare Advantage members with chronic kidney disease (CKD) stages 3B–5.
Launched July 1, this partnership builds on the organizations' long-standing collaboration in end stage kidney disease and expands earlier into the disease journey, when intervention can have the greatest impact.As
Aug 18, 2026
NORTHAMPTON, MA / ACCESS Newswire / August 18, 2026 / Throughout DaVita's 25+ year history, we've led the way in patient-centered kidney care. Our work has played a key role in reducing hospitalizations, extending lifespan and helping propel the kidney ...
Aug 13, 2026
DaVita’s second quarter results surpassed Wall Street’s revenue and adjusted profit expectations, but the market response was notably negative. Management attributed this to a mix of operational and industry-specific challenges, including flat treatment volumes and sequential declines in revenue per treatment, primarily due to a less favorable commercial mix and reduced revenue from phosphate binders. CEO Javier Rodriguez emphasized, “Our growth is mainly performance clinical—that expands life,
Aug 12, 2026
NORTHAMPTON, MA / ACCESS Newswire / August 12, 2026 /Working Together, Working for Better At DaVita, people are the foundation of our community and the driving force behind our pursuit of a healthier tomorrow for all. Rooted in our identity as a community ...
Aug 11, 2026
Mortality gains drove treatment growth despite payor mix headwinds.
Though DaVita has outpaced the broader market over the past year, Wall Street analysts maintain a cautiously optimistic outlook on the stock’s prospects.
Aug 8, 2026
DaVita stock has climbed 69.6% over the past three years. After a recent pullback and a strong value score, the current price still raises questions about how much upside investors are actually paying for. Over the past 3 years, DaVita has returned 69.6%, which puts recent share price weakness in the context of a longer period of strong gains. Support for the valuation can come from expectations that DaVita benefits from growing demand for integrated kidney and metabolic care. Execution...
Aug 7, 2026
TD Cowen analyst Ryan Langston upgrades DaVita (NYSE:DVA) from Hold to Buy and lowers the price target from $201 to $220.
DaVita HealthCare Partners Inc. (NYSE:DVA) shares gained around 2.
Truist Securities analyst David Macdonald maintains DaVita (NYSE:DVA) with a Hold and lowers the price target from $250 to $215.
Aug 6, 2026
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Aug 5, 2026
DVA's second-quarter 2026 results show profit growth, but narrowing margins and a weaker commercial mix weigh on the performance.
